Company News Summary | 31 Jan 2018
Click the print icon in your browser to print this report. Currency is in AUD unless otherwise specified
Starpharma Holdings Announces to Commence DEP Cabazitaxel Phase 1/2 Trial
11:09:00 | Associate analysts
Original annuncemenet:Starpharma to commence DEP cabazitaxel phase 1/2 trial
Starpharma Holdings announced that it has received regulatory and ethics approvals to commence its phase 1/2 clinical trial for DEP cabazitaxel. The objectives of the trial are to evaluate the safety, tolerability and pharmacokinetics of DEP cabazitaxel, to define a recommended phase 2 dose (RP2D), and then to determine anti-tumour efficacy of the product in select tumour types. The trial will be conducted at multiple sites, with Guy's Hospital London and University College London Hospital (UCLH) in the UK being the first sites to open for recruitment. Further sites will open and commence recruitment as dose escalation progresses and the phase 2 part of the trial gets underway. 35 patients will be enrolled across the phase 1/2 trial.
|This report appeared on www.morningstar.com.au||2019 Morningstar Australasia Pty Limited|
© Copyright 2019 Morningstar Australasia Pty Ltd ABN: 95 090 665 544 ("Morningstar"), AFSL no 240892. (a subsidiary of Morningstar, Inc.). This information is to be used for personal, non-commercial purposes only. No reproduction is permitted without the prior written content of Morningstar. Some of the material provided is published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO").